Immix Biopharma (NASDAQ:IMMX) Shares Gap Up – What’s Next?

Immix Biopharma, Inc. (NASDAQ:IMMX)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $9.13, but opened at $9.92. Immix Biopharma shares last traded at $9.5860, with a volume of 285,624 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IMMX. Bank of America initiated coverage on Immix Biopharma in a research note on Thursday. They issued a “buy” rating and a $27.00 price target on the stock. HC Wainwright raised their price objective on Immix Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a report on Friday, May 22nd. Wall Street Zen cut shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Citizens Jmp reaffirmed a “market outperform” rating and set a $23.00 target price on shares of Immix Biopharma in a report on Friday, March 27th. Finally, Mizuho increased their target price on shares of Immix Biopharma from $14.00 to $15.00 and gave the company an “outperform” rating in a research report on Monday, March 30th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Immix Biopharma presently has a consensus rating of “Moderate Buy” and an average target price of $20.67.

Immix Biopharma Stock Up 1.4%

The business has a 50-day moving average price of $9.21 and a 200-day moving average price of $7.71. The firm has a market capitalization of $503.79 million, a PE ratio of -10.04 and a beta of 0.10.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. On average, equities research analysts anticipate that Immix Biopharma, Inc. will post -0.7 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of IMMX. Allworth Financial LP purchased a new stake in shares of Immix Biopharma in the fourth quarter valued at about $30,000. Mathes Company Inc. purchased a new position in Immix Biopharma during the fourth quarter worth about $56,000. Balyasny Asset Management L.P. acquired a new position in Immix Biopharma in the 4th quarter valued at about $67,000. Kera Capital Partners Inc. purchased a new stake in shares of Immix Biopharma in the 4th quarter valued at approximately $68,000. Finally, Velan Capital Investment Management LP grew its stake in shares of Immix Biopharma by 40.0% in the 3rd quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company’s stock valued at $73,000 after buying an additional 10,000 shares during the period. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.